STOCK TITAN

Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 9:10 AM ET on Tuesday, August 11, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira                                                                           

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.  In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

 


Pacira BioSciences, Inc.

NASDAQ:PCRX

PCRX Rankings

PCRX Latest News

PCRX Stock Data

1.40B
46.02M
1.21%
108.08%
8.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TAMPA

About PCRX

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.